



Preferred Drug List

NEW DRUG REVIEW

Proprietary Name: Evamist™

Common Name: Estradiol Spray

PDL Category: Estrogens - Patches

<u>Comparable Products</u>	<u>Preferred Drug List/ Recommended Drug List Status</u>
Divigel® (Estradiol topical)	Non-Preferred
Elestrin™ (Estradiol topical)	Non-Preferred
Vivelle Patch/Dot® (Estradiol Transdermal)	Preferred

Summary

Indications and Usage: Moderate-to-severe vasomotor symptoms

Mechanism of Action: Binds to estrogen receptors in estrogen-responsive tissues to maintain gender characteristics and reproductive system

Dosage Forms: Spray; 1.53mg estradiol/spray

Recommended Dosage: Start with one spray once daily to forearm; may increase to two or three sprays daily as needed. Women with an intact uterus should combine Evamist™ with a progestin product to reduce endometrial cancer risk

Common Adverse Drug Reactions: Breast tenderness, headache, nausea, back pain, nasopharyngitis

Contraindications: Undiagnosed abnormal genital bleeding, history of breast cancer, history of estrogen-dependent neoplasia, history of or active DVT or pulmonary embolism, active or recent arterial thromboembolic disease, hepatic dysfunction, hypersensitivity to any ingredients of the compound, known or suspected pregnancy

Manufacturer: Vivus, Inc.

Analysis: Evamist™ delivers sustained circulating concentrations of estradiol by way of a daily administered topical spray. Clinical studies document a dose dependent response that reduces both the frequency and severity of daily hot flashes. Unpublished studies show a 68-78% reduction in hot flashes compared to placebo (*The Medical Letter, August 27, '07*). At the time of the product's release, however, Evamist™ had only been compared to placebo. When compared to other preferred, topical estradiol products on the Preferred Drug List (PDL), Evamist™ requires daily application and is only indicated for vasomotor symptoms whereas other products are dosed twice weekly and are indicated for treatment of other menopausal symptoms as well making them more cost effective. Therefore, it is recommended that Evamist™ be added to the PDL as a non-preferred drug.

IME Recommendation:

<input type="checkbox"/> Preferred Drug	<input type="checkbox"/> Recommended Drug
<input checked="" type="checkbox"/> Non-Preferred Drug	<input type="checkbox"/> Non-Recommended Drug
<input type="checkbox"/> Preferred Drug with Conditions	